OncRef

Clinical Trial: NCT05960578

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

Status:

TERMINATED

Phase:

Phase 2

Lead Sponsor:University of Washington
Information Provided By:University of Washington
Last Update Posted:2026-10-19

Study Overview

Brief Summary

This phase II trial tests how well golimumab and apalutamide work in treating patients with castration resistant prostate cancer. Golimumab is in a class of medications called tumor necrosis factor (TNF) inhibitors. It works by blocking the action of TNF, a substance in the body that causes inflammation. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of cancer cells. Giving golimumab and apalutamide may work better in treating patients with castration-resistant prostate cancer.

Official Title

TRAMP: Tumor Necrosis Factor- α Blockade and AR Inhibition in Men With CRPC

Conditions

Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8

Intervention / Treatment

  • Drug: Apalutamide
  • Procedure: Biopsy
  • Procedure: Biospecimen Collection
  • Procedure: Computed Tomography
  • Drug: Golimumab
  • Procedure: Magnetic Resonance Imaging
  • Procedure: PSMA PET Scan
  • Procedure: Bone Scan

Other Study ID Numbers

  • RG1123487
  • NCI-2023-04887
  • FHIRB0020135

Start Date (Actual)

2024-05-23

Primary Completion Date (Actual)

2025-07-29

Study Completion Date (Actual)

2026-04-14

Enrollment (Actual)

8

Study Type

Interventional

Phase

Phase 2